Nutritional and Metabolic Diseases

Symptoms and General Pathology

All Conditions

Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Diseases and Abnormalities at or Before Birth

Rare Diseases

Overweight

Syndrome

Obesity

Polycystic Ovary Syndrome

Insulin Resistance

Hyperandrogenism

Hyperinsulinism

Metabolic Diseases

Glucose Metabolism Disorders

Cysts

Ovarian Cysts

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Gonadal Disorders

Endocrine System Diseases

Disorders of Sex Development

46, XX Disorders of Sex Development

Congenital Abnormalities

Urogenital Abnormalities

Adrenal Hyperplasia, Congenital

Adrenogenital Syndrome

Male Urogenital Diseases

Congenital Adrenal Hyperplasia

21-hydroxylase Deficiency

Hypoglycemic Agents

All Drugs and Chemicals

Other Dietary Supplements

Insulin

Insulin, Globin Zinc

Acidophilus

A diet based on general recommendations for people with insulin resistance for 20 weeks.

Lactobacillus rhamnosus for 20 weeks, (2x 6×10 9 CFU/per capsulex); A diet based on general recommendations for people with insulin resistance.

Nutrition intervention focused on the treatment of insulin resistance + Lactobacillus rhamnosus supplementation (6x10 9 of lactobacillus rhamnosus x 2 times a day) (35 people).

Lactobacillus group

Nutritional intervention focused on the treatment of insulin resistance (35 subjects).

Dietary group

The effect of Lactobacillus rhamnosus supplementation on body weight, hyperandrogenism and insulin resistance in overweight and obesity women with Polycystic Ovary Syndrome will be analysed.

Lactobacillus Rhamnosus and PCOS Treatment

The Effect of Lactobacillus Rhamnosus Supplementation on Body Mass, Hyperandrogenism and Insulin Resistance in Overweight and Obese Polycystic Ovary Syndrome Women - Randomized Nutritional Study

Fasting insulin concentration (uU/ml) will be measured before and after 2 hours of 75g glucose drink. Insulin resistance will be measured before and after 20 weeks of the intervention.

Fasting glucose concentration (mg/dL) will be measured before and after 2 hours of 75g glucose drink. OGTT will be measured before and after 20 weeks of the intervention. Fating glucose and fasting insulin concentrations will be combined to report HOMA-IR index (homeostatic model assessment of insulin resistance).

Testosterone (ng/mL) concentrations will measured at baseline and after 20 weeks of the intervention. Results of testosterone level and SHBG level will be combined to report FAI index (index of free androgen).

DHEA-SO4 (umol/L) concentrations will measured at baseline and after 20 weeks of the intervention. Results of testosterone level and SHBG level will be combined to report FAI index (index of free androgen).

SHBG (nmol/L) concentrations will measured at baseline and after 20 weeks of the intervention. Results of testosterone level and SHBG level will be combined to report FAI index (index of free androgen).

Results of testosterone level and SHBG level will be combined to report FAI index (index of free androgen).

Body weight (kg) will be assessment at baseline and after 20 weeks of the intervention.

Body height (cm) will be assessment at baseline of the intervention.

Fat mass (%), fat free mass (%) will be assessment at baseline and after 20 weeks of the intervention.

Cholesterole (mg/dL) will be measured at baseline and after 20 weeks of the intervention

Triglicerydes (mg/dL) will be measured at baseline and after 20 weeks of the intervention

High density lipoprotein HDL (mg/dL) will be measured at baseline and after 20 weeks of the intervention

Low density lipoprotein LDL (mg/dL) will be measured at baseline and after 20 weeks of the intervention

Qualitative and quantitative determination of the composition of gut microbiota will be assessment at baseline and after 20 weeks of the intervention

B-glucuronidase and B-glucosiadase activity in stoolen sample will be assessment at baseline and after 20 weeks of the intervention

Assessment of short-chain fatty acids will be assessment at baseline and after 20 weeks of the intervention

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Lactobacillus Rhamnosus and PCOS Treatment	NCT03902301	Insulin Resista... Polycystic Ovar... Hyperandrogenis... Obesity	Lactobacillus g... Dietary group	18 Years - 40 Years	Poznan University of Life Sciences
Lactobacillus Rhamnosus and PCOS Treatment	NCT03902301	Insulin Resista... Polycystic Ovar... Hyperandrogenis... Obesity	Lactobacillus g... Dietary group	18 Years - 40 Years	Poznan University of Life Sciences
Lactobacillus Rhamnosus and PCOS Treatment	NCT03902301	Insulin Resista... Polycystic Ovar... Hyperandrogenis... Obesity	Lactobacillus g... Dietary group	18 Years - 40 Years	Poznan University of Life Sciences

Spots Global Cancer Trial Database for dietary group